As part of the National Psoriasis Foundation’s (NPF) efforts to improve healthcare outcomes and grow the field of psoriatic disease research through education, we are excited to continue our Mentor Program.
Developed in collaboration with the NPF Medical Board and Emeritus Medical Board, composed of key opinion leaders in the psoriatic disease field, the mentorship program will allow newly practicing physicians and researchers to connect with experts who have many years of experience treating complex psoriatic disease cases. Through the mentorship program, you will have access to these leaders for feedback on challenging cases and for career guidance.
Types of Mentorship
Early career professional member physicians and researchers may apply for two types of mentorship provided by our Medical Board and Emeritus Medical Board Members:
NPF early career professional members who participate in the distance mentorship program will be matched with a member of the NPF Medical Board or Emeritus Board. The early career member will then be able to contact their mentor by phone and email. A requirement of this program is that the participant pairs communicate quarterly, at minimum, to ensure the opportunity to establish a relationship and receive appropriate feedback.
Early career professional member physicians or researchers who participate in the in-person shadowing program will be paired with a physician or researcher mentor who has agreed to open their clinic or laboratory for shadowing.
NPF will provide a travel stipend of up to $1000. The stipend may be used towards economy airfare and standard, single room accommodations. All travel must adhere to the Foundation’s travel and reimbursement policy, which will be provided to all mentees once selected.
Physician participants will accompany their mentor during patient visits in order to see a broader range of psoriatic disease cases and learn new treatment strategies. In addition, the physicians will learn more about the unique insurance requirements for psoriatic disease, including step therapy, prior authorizations and appealing denials for treatments. Participation in the clinic shadowing program is limited. Clinical shadowing will be offered up to one week.
Early career researchers who are interested in pursuing further studies in psoriatic disease may also apply for the shadowing program. These early-career researchers will shadow established researchers in the laboratory, where they may observe, and, if properly trained and research protocols allow, participate in ongoing research projects. This shadowing program will allow early-career researchers the opportunity to view current psoriatic disease research projects, learn new lab techniques, and establish a mentor that they can continue to stay in contact with as their own research projects evolve.
The NPF Mentor Program is open to all early career professional members of the National Psoriasis Foundation, including dermatologists, rheumatologists, residents, fellows, researchers, NPs and PAs.
Applications will be reviewed by the NPF and evaluated for thoroughness and thoughtfulness of application responses. The applicants who qualify will be matched to a mentorship position that best matches their preferences and abilities. Applicants will be notified of their status one month after the application deadline.
The 2019 National Psoriasis Foundation Mentor In-Person Shadowing Program is CME accredited!
The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Psoriasis Foundation designates this live activity for a maximum of 40.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
We are now accepting applications for 2019, apply now.
If you have any questions about the NPF Mentor Program or the application process, please contact [email protected].
This activity is supported by educational grants from: Amgen, Lilly and Valeant Pharmaceuticals